Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality.

Sorror ML, Gooley TA, Maclean KH, Hubbard J, Marcondes MA, Torok-Storb BJ, Tewari M.

Bone Marrow Transplant. 2019 Jul;54(7):973-979. doi: 10.1038/s41409-018-0352-9. Epub 2018 Oct 2.

2.

Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounterâ„¢ system.

Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL.

Mol Oncol. 2014 May;8(3):669-78. doi: 10.1016/j.molonc.2014.01.010. Epub 2014 Jan 31.

3.

Acute pyelonephritis in renal allografts: a new role for microRNAs?

Oghumu S, Bracewell A, Nori U, Maclean KH, Balada-Lasat JM, Brodsky S, Pelletier R, Henry M, Satoskar AR, Nadasdy T, Satoskar AA.

Transplantation. 2014 Mar 15;97(5):559-68. doi: 10.1097/01.TP.0000441322.95539.b3.

4.

Identification of sensitive serum microRNA biomarkers for radiation biodosimetry.

Jacob NK, Cooley JV, Yee TN, Jacob J, Alder H, Wickramasinghe P, Maclean KH, Chakravarti A.

PLoS One. 2013;8(2):e57603. doi: 10.1371/journal.pone.0057603. Epub 2013 Feb 25.

5.

Mitochondrial dysfunction in ataxia-telangiectasia.

Valentin-Vega YA, Maclean KH, Tait-Mulder J, Milasta S, Steeves M, Dorsey FC, Cleveland JL, Green DR, Kastan MB.

Blood. 2012 Feb 9;119(6):1490-500. doi: 10.1182/blood-2011-08-373639. Epub 2011 Dec 5.

6.

ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS.

Alexander A, Cai SL, Kim J, Nanez A, Sahin M, MacLean KH, Inoki K, Guan KL, Shen J, Person MD, Kusewitt D, Mills GB, Kastan MB, Walker CL.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4153-8. doi: 10.1073/pnas.0913860107. Epub 2010 Feb 16. Erratum in: Proc Natl Acad Sci U S A. 2012 May 22;109(21):8352.

7.

Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine.

Höglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA.

Blood. 2009 Apr 30;113(18):4281-8. doi: 10.1182/blood-2008-10-183475. Epub 2009 Jan 29.

8.

Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.

Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ.

Blood. 2008 Oct 1;112(7):2917-26. doi: 10.1182/blood-2007-12-130823. Epub 2008 Jul 18.

9.

Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis.

Maclean KH, Dorsey FC, Cleveland JL, Kastan MB.

J Clin Invest. 2008 Jan;118(1):79-88. Erratum in: J Clin Invest. 2008 Apr;118(4):1584.

10.

Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis.

Loehberg CR, Thompson T, Kastan MB, Maclean KH, Edwards DG, Kittrell FS, Medina D, Conneely OM, O'Malley BW.

Cancer Res. 2007 Dec 15;67(24):12026-33.

11.

Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis.

Maclean KH, Kastan MB, Cleveland JL.

Mol Cancer Res. 2007 Jul;5(7):705-11.

12.

Ceramide-induced G2 arrest in rhabdomyosarcoma (RMS) cells requires p21Cip1/Waf1 induction and is prevented by MDM2 overexpression.

Phillips DC, Hunt JT, Moneypenny CG, Maclean KH, McKenzie PP, Harris LC, Houghton JA.

Cell Death Differ. 2007 Oct;14(10):1780-91. Epub 2007 Jul 13.

13.

Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.

Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, MacLean KH, Chung L, Yang C, Spruck C, Boyd K, Reed SI, Cleveland JL.

EMBO J. 2007 May 16;26(10):2562-74. Epub 2007 Apr 26.

14.

ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome.

Schneider JG, Finck BN, Ren J, Standley KN, Takagi M, Maclean KH, Bernal-Mizrachi C, Muslin AJ, Kastan MB, Semenkovich CF.

Cell Metab. 2006 Nov;4(5):377-89.

15.

Mechanisms of group B streptococcal-induced apoptosis of murine macrophages.

Ulett GC, Maclean KH, Nekkalapu S, Cleveland JL, Adderson EE.

J Immunol. 2005 Aug 15;175(4):2555-62.

16.

Nfkb 1 is dispensable for Myc-induced lymphomagenesis.

Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL.

Oncogene. 2005 Sep 15;24(41):6231-40.

PMID:
15940251
17.

Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation.

Nilsson JA, Maclean KH, Keller UB, Pendeville H, Baudino TA, Cleveland JL.

Mol Cell Biol. 2004 Feb;24(4):1560-9.

18.

Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.

Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, MacLean KH, Han J, Chittenden T, Ihle JN, McKinnon PJ, Cleveland JL, Zambetti GP.

Cancer Cell. 2003 Oct;4(4):321-8.

19.

c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL.

Maclean KH, Keller UB, Rodriguez-Galindo C, Nilsson JA, Cleveland JL.

Mol Cell Biol. 2003 Oct;23(20):7256-70.

20.

Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.

Baudino TA, Maclean KH, Brennan J, Parganas E, Yang C, Aslanian A, Lees JA, Sherr CJ, Roussel MF, Cleveland JL.

Mol Cell. 2003 Apr;11(4):905-14.

21.

ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma.

Hernan R, Fasheh R, Calabrese C, Frank AJ, Maclean KH, Allard D, Barraclough R, Gilbertson RJ.

Cancer Res. 2003 Jan 1;63(1):140-8.

22.

c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression.

Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN, Cleveland JL.

Genes Dev. 2002 Oct 1;16(19):2530-43.

23.

Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.

Maclean KH, Cleveland JL, Porter JB.

Blood. 2001 Dec 15;98(13):3831-9.

24.

The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators.

Abeysinghe RD, Roberts PJ, Cooper CE, MacLean KH, Hider RC, Porter JB.

J Biol Chem. 1996 Apr 5;271(14):7965-72.

Supplemental Content

Loading ...
Support Center